Serum sICAM-1 and Galectin-3 Levels in Diabetic Patients with COVID-19
Viruses · 2025
DOI: 10.3390/v17071005 ↗Kurz gefasst
Beobachtungsstudie in der Zeitschrift Viruses, 2025. Verfasst von Busra Karahan und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine, Erzurum Regional Training and Research Hospital, Erzurum 25240, Türkiye. Hauptthemen laut MEDLINE: COVID-19, Diabetes Mellitus, Type 2, Intercellular Adhesion Molecule-1, Galectin 3. Die Arbeit nennt 38 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Introduction
This study aimed to evaluate the diagnostic and prognostic value of soluble intercellular adhesion molecule-1 (sICAM-1) and galectin-3 in patients with type 2 diabetes mellitus (T2D) diagnosed with coronavirus disease 2019 (COVID-19). Participants and Method: This prospective observational study included 45 adult patients (≥18 years) with T2D and confirmed COVID-19 who were followed in the Infectious Diseases and Clinical Microbiology departments between May and June 2022. The control group consisted of 45 healthy volunteers without chronic illness who were presented to the internal medicine outpatient clinic. In addition to routine laboratory biomarkers assessed at hospital admission, the serum levels of sICAM-1 and galectin-3 were measured via ELISA kits.
Results
The median age of the patients was 66 years (range: 41–77), and 23 (51.1%) were male. Hypertension was the most common comorbidity in addition to diabetes. Compared with those in the control group, the serum levels of both galectin-3 and sICAM-1 were significantly elevated in patients with COVID-19 and T2D (p < 0.001). However, there was no significant difference in galectin-3 or sICAM-1 levels between survivors and nonsurvivors (p = 0.240 and p = 0.266, respectively).
Conclusion
Galectin-3 and sICAM-1 demonstrated stronger diagnostic utility than conventional biomarkers in T2D patients with COVID-19. The elevated levels of these markers may reflect the underlying systemic inflammation observed in diabetic patients with COVID-19. The strong correlation between galectin-3 and sICAM-1 suggests a potential link in their inflammatory regulation, although causality cannot be inferred.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Internal Medicine, Erzurum Regional Training and Research Hospital, Erzurum 25240, Türkiye.
- Department of Infectious Diseases and Clinical Microbiology, Erzurum Regional Training and Research Hospital, Erzurum 25240, Türkiye.
- Department of Medical Biochemistry, Atatürk University School of Medicine, Erzurum 25240, Türkiye.
- Department of Endocrinology and Metabolism, Faculty of Medicine, Recep Tayyip Erdogan University, Rize 53100, Türkiye.
ORCID-Profile: Busra Karahan, Dogan Nasir Binici, Sibel İba Yilmaz, Filiz Mercantepe
Zitieren
APA
Karahan, B., Binici, D. N., Karasahin, O., Yilmaz, S. İ., Kiziltunc, A., & Mercantepe, F. (2025). Serum sICAM-1 and Galectin-3 Levels in Diabetic Patients with COVID-19. Viruses. https://doi.org/10.3390/v17071005
Vancouver
Karahan B, Binici DN, Karasahin O, Yilmaz Sİ, Kiziltunc A, Mercantepe F. Serum sICAM-1 and Galectin-3 Levels in Diabetic Patients with COVID-19. Viruses. 2025. doi:10.3390/v17071005
BibTeX
@article{Karahan2025,
author = {Karahan, Busra and Binici, Dogan Nasir and Karasahin, Omer and Yilmaz, Sibel İba and Kiziltunc, Ahmet and Mercantepe, Filiz},
title = {Serum sICAM-1 and Galectin-3 Levels in Diabetic Patients with COVID-19},
journal = {Viruses},
year = {2025},
doi = {10.3390/v17071005}
}
EUVIMED